PT - JOURNAL ARTICLE AU - Porter, Michael K. AU - Viloria Winnett, Alexander AU - Hao, Linhui AU - Shelby, Natasha AU - Reyes, Jessica A. AU - Schlenker, Noah W. AU - Romano, Anna E. AU - Tognazzini, Colton AU - Feaster, Matthew AU - Goh, Ying-Ying AU - Gale, Michael AU - Ismagilov, Rustem F. TI - The ratio between SARS-CoV-2 RNA viral load and culturable viral titer differs depending on stage of infection AID - 10.1101/2023.07.06.23292300 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.06.23292300 4099 - http://medrxiv.org/content/early/2023/07/12/2023.07.06.23292300.short 4100 - http://medrxiv.org/content/early/2023/07/12/2023.07.06.23292300.full AB - Analysis of incident, longitudinal RNA viral loads in saliva and nasal swabs and culturable viral titers in nasal swabs collected twice-daily by a tricenarian male infected with SARS-CoV-2 revealed the ratio between viral load and viral titer can be five orders of magnitude higher during early infection than late infection.Competing Interest StatementR.F.I. is a cofounder, consultant, and a director and has stock ownership of Talis Biomedical Corp. All other co-authors report no competing interests.Funding StatementThis study is based on research funded in part by the Bill & Melinda Gates Foundation (INV-023124). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. This work was also funded by the Ronald and Maxine Linde Center for New Initiatives at the California Institute of Technology and the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology. A.V.W. is supported by a UCLA DGSOM Geffen Fellowship. MG and LH were supported by National Institutes of Health grant AI151698 for the United World Antiviral Research Network (UWARN) component of the Centers for Research in Emerging Infectious Disease (CREID).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the California Institute of Technology gave ethical approval for this work (Protocol #20-1026)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying the results presented in the study are available at CaltechDATA at https://data.caltech.edu/records/cgf4q-byr92. https://data.caltech.edu/records/cgf4q-byr92